石藥集團(01093.HK)單克隆抗體藥物獲臨床試驗批准

You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.

Hong Kong

Open Account

石藥集團(01093.HK)單克隆抗體藥物獲臨床試驗批准

阿思達克 11-05 20:09

石藥集團(01093.HK)公布，集團開發的單克隆抗體藥物(SYS6011)已獲中國國家藥品監督管理局批准，可於內地開展臨床研究。SYS6011可與腫瘤細胞及腫瘤浸潤的免疫細胞表面的特異性受體結合，通過解除腫瘤微環境的免疫抑制，達到殺傷腫瘤細胞的作用。

石藥集團(01093.HK)

Relevant Stocks

石藥集團(01093.HK)

Customer Service Hotline︰+852 3018 4526

Email︰cs@usmarthk.com

Address︰26/F, 2606, 308 Des Voeux Road Central, Sheung Wan, Hong Kong

WhatsApp︰+852 5989 2641

Join the Community：

uSmart Securities Limited

is a licensed corporation approved by the Hong Kong SFC (CE number: BJA907), provides securities trading services and is subject to its supervision.

Market News

石藥集團(01093.HK)單克隆抗體藥物獲臨床試驗批准

Services

About Us

Agreement Statement